Processa Pharmaceuticals Stock Performance
| PCSA Stock | USD 3.36 0.10 2.89% |
The company holds a Beta of 0.21, which implies not very significant fluctuations relative to the market. As returns on the market increase, Processa Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Processa Pharmaceuticals is expected to be smaller as well. At this point, Processa Pharmaceuticals has a negative expected return of -0.47%. Please make sure to check Processa Pharmaceuticals' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Processa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.73 | Five Day Return 22.26 | Year To Date Return 18.09 | Ten Year Return (99.75) | All Time Return (99.96) |
Last Split Factor 1:25 | Dividend Date 2019-12-23 | Last Split Date 2025-12-17 |
1 | Reversal indicators forming on Processa Pharmaceuticals Inc. stock - July 2025 Catalysts High Accuracy Swing Trade Signals - newser.com | 10/22/2025 |
2 | Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 23 PCS499 Study in FSGS at ASN Kidney Week 2025 | 11/05/2025 |
3 | Is Processa Pharmaceuticals Inc. meeting your algorithmic filter criteria - 2025 Big Picture Free High Return Stock Watch Alerts - newser.com | 11/11/2025 |
4 | Acquisition by Patrick Lin of 3 shares of Processa Pharmaceuticals subject to Rule 16b-3 | 11/12/2025 |
5 | Retail Trends Can Processa Pharmaceuticals Inc. stock outperform in 2025 bull market - Rate Cut Free Safe Capital Growth Stock Tips - Fundao Cultural do Par | 11/14/2025 |
6 | Will Processa Pharmaceuticals Inc. stock benefit from infrastructure spending - Market Activity Report Technical Confirmation Trade Alerts - newser.com | 11/19/2025 |
7 | Processa Pharmaceuticals Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 11/28/2025 |
8 | Acquisition by Neal James R of 300000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/10/2025 |
9 | Will Processa Pharmaceuticals Spend Its Cash Wisely | 12/17/2025 |
10 | Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - morningsun.net | 12/26/2025 |
11 | Acquisition by Wendy Guy of 150000 shares of Processa Pharmaceuticals at 0.198 subject to Rule 16b-3 | 12/30/2025 |
12 | Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Massillon Independent | 01/02/2026 |
13 | Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance - TipRanks | 01/07/2026 |
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | -3244.00 |
Processa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,103 in Processa Pharmaceuticals on October 11, 2025 and sell it today you would lose (767.00) from holding Processa Pharmaceuticals or give up 69.54% of portfolio value over 90 days. Processa Pharmaceuticals is currently does not generate positive expected returns and assumes 19.2193% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Processa, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Processa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Processa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Processa Pharmaceuticals, and traders can use it to determine the average amount a Processa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0247
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCSA |
Based on monthly moving average Processa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Processa Pharmaceuticals by adding Processa Pharmaceuticals to a well-diversified portfolio.
Processa Pharmaceuticals Fundamentals Growth
Processa Stock prices reflect investors' perceptions of the future prospects and financial health of Processa Pharmaceuticals, and Processa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Processa Stock performance.
| Return On Equity | -2.71 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 1.47 M | ||||
| Shares Outstanding | 2.27 M | ||||
| Price To Book | 1.33 X | ||||
| EBITDA | (12.05 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 73.51 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 2.76 X | ||||
| Cash Flow From Operations | (11.25 M) | ||||
| Earnings Per Share | (28.75) X | ||||
| Market Capitalization | 7.84 M | ||||
| Total Asset | 3.23 M | ||||
| Retained Earnings | (87.22 M) | ||||
| Working Capital | 340.99 K | ||||
About Processa Pharmaceuticals Performance
By analyzing Processa Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Processa Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Processa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Processa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 635.83 | 342.18 | |
| Return On Tangible Assets | (3.30) | (3.47) | |
| Return On Capital Employed | (8.17) | (7.76) | |
| Return On Assets | (3.30) | (3.47) | |
| Return On Equity | (8.03) | (7.63) |
Things to note about Processa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Processa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Processa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Processa Pharmaceuticals generated a negative expected return over the last 90 days | |
| Processa Pharmaceuticals has high historical volatility and very poor performance | |
| Processa Pharmaceuticalshas 3,454,719 shares shorted by Processa Pharmaceuticals investors is about 100% of outstending shares | |
| Net Loss for the year was (11.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Processa Pharmaceuticals currently holds about 12.06 M in cash with (11.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Processa Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Processa Pharmaceuticals Regains Nasdaq Minimum Bid Compliance - TipRanks |
- Analyzing Processa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Processa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Processa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Processa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Processa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Processa Pharmaceuticals' stock. These opinions can provide insight into Processa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Processa Stock analysis
When running Processa Pharmaceuticals' price analysis, check to measure Processa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Processa Pharmaceuticals is operating at the current time. Most of Processa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Processa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Processa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Processa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |